Impact of Tumor Load in Melanoma on Lymph Node Involvement and Survival
Author Information
Author(s): Guggenheim M, Dummer R, Jung F J, Mihic-Probst D, Steinert H, Rousson V, French L E, Giovanoli P
Primary Institution: University Hospital Zurich
Hypothesis
Does sentinel lymph node tumor burden predict additional lymph node involvement and disease-free survival in melanoma patients?
Conclusion
Sentinel lymph node tumor load does not predict non-sentinel lymph node positivity, and patients with micrometastases have worse disease-free survival compared to those with tumor-free sentinel lymph nodes.
Supporting Evidence
- 30.8% of patients with SLN macrometastases had non-SLN positivity.
- 51.3% of patients with SLN macrometastases experienced tumor recurrences.
- The 2-mm cutoff for SLN tumor load accurately predicts differences in disease-free survival.
Takeaway
This study looked at melanoma patients and found that just because a sentinel lymph node has cancer doesn't mean other lymph nodes will too, but having more cancer in the sentinel node can lead to more recurrences.
Methodology
Retrospective analysis of 392 melanoma patients who underwent sentinel lymph node biopsy and were followed for a median of 38.8 months.
Potential Biases
Potential selection bias due to the exclusion of patients who refused completion lymph node dissection.
Limitations
The study is retrospective and conducted at a single center, which may limit the generalizability of the findings.
Participant Demographics
392 patients with cutaneous malignant melanoma, including 224 males (57.1%) and 168 females (42.9%), with a mean age of 53 years.
Statistical Information
P-Value
P=0.005
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website